Boston Scientific director buys 2,040 company shares

BOSTON SCIENTIFIC CORP (BSX) director Susan E. Morano reported purchasing 2,040 shares of common stock on 2026-08-25 in an open-market or private transaction at $49.2195 per share.

Rhea-AI Filing Summary

BOSTON SCIENTIFIC CORP (BSX) director Susan E. Morano reported purchasing 2,040 shares of common stock on 2026-08-25 in an open-market or private transaction at $49.2195 per share. Following this buy, she directly holds 13,784 shares of Boston Scientific common stock. The Rule 10b5-1 trading plan checkbox was not marked for this transaction.

Insider Trade Summary

Net Buyer: 2,040 shares

Net Buy 1 txn

Insider Morano Susan E

Role Director

Bought 2,040 shs ($100K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	2,040	$49.2195	$100K

Holdings After Transaction: Common Stock — 13,784 shares (Direct)

Key Figures

Shares purchased: 2,040 shares of Common Stock Purchase price per share: $49.2195 per share Shares owned after transaction: 13,784 shares of Common Stock

3 metrics

Shares purchased 2,040 shares of Common Stock Non-derivative purchase on 2026-08-25 (transaction code P)

Purchase price per share $49.2195 per share Open-market or private transaction on 2,040 BSX shares

Shares owned after transaction 13,784 shares of Common Stock Direct ownership following the 2026-08-25 purchase

Key Terms

Purchase in open market or private transaction, Rule 10b5-1, beneficial ownership

3 terms

Purchase in open market or private transaction financial

"transaction code description is “Purchase in open market or private transaction”"

Rule 10b5-1 regulatory

"The Rule 10b5-1 trading plan checkbox was not checked for this filing"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

beneficial ownership regulatory

"Footnotes may include disclaimers of beneficial ownership by the reporting person"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BSX director Susan E. Morano report?

Susan E. Morano reported a purchase of 2,040 BSX common shares on 2026-08-25 in an open-market or private transaction at $49.2195 per share, increasing her direct holdings to 13,784 shares.

At what price did Susan E. Morano buy BSX shares?

Susan E. Morano bought 2,040 BSX shares at a price of $49.2195 per share in a reported open-market or private transaction dated 2026-08-25.

How many BSX shares does Susan E. Morano own after this transaction?

After the reported transaction, Susan E. Morano directly holds 13,784 shares of Boston Scientific common stock, as stated in the Form 4 data.

Was Susan E. Morano’s BSX trade under a Rule 10b5-1 plan?

No. The filing’s Rule 10b5-1 trading plan checkbox is not checked, indicating the reported purchase was not affirmed as made pursuant to a Rule 10b5-1 trading plan.

What transaction code was used for Susan E. Morano’s BSX trade?

The transaction used code P, described as a “Purchase in open market or private transaction” for 2,040 shares of Boston Scientific common stock at $49.2195 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/26/2026 - 06:47 PM EDT Accepted by SEC EDGAR 08/26/2026 - 06:46 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Morano Susan E

(Last) (First) (Middle)

300 BOSTON SCIENTIFIC WAY

(Street)

MARLBOROUGH MASSACHUSETTS 01752-1234

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/25/2026		P		2,040	A	$49.2195	13,784	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Susan Thompson, Attorney-in-Fact	08/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)